Haemonetics (HAE) FY2015 results: revenue $910 million, down 3.0% on the year
Haemonetics Corp. (HAE) reported revenue of $910 million for fiscal 2015, the year ended 28 March 2015, down 3.0% on the year before. Net income was $17 million, down 51.9%, and diluted earnings per share $0.32. The figures are the company's own, from the 10-K it filed with the SEC on 22 May 2015.
Revenue
$910 million
-3.0% on the year
FY2009FY2015
Operating margin
4.5%
4.9% a year earlier
FY2009FY2015
Net income
$17 million
-51.9% on the year
FY2009FY2015
Diluted EPS
$0.32
-52.2% on the year
FY2009FY2015
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2015
FY2014
FY2013
On the year
Last 8 years
Revenue
910
939
892
-3.0%
Cost of revenue
476
470
464
+1.2%
Gross profit
434
468
428
-7.2%
Gross margin
47.7%
49.9%
48.0%
Research and development
54.2
54.2
44.4
-0.0%
Selling, general and administrative
337
366
323
-7.9%
Operating income
40.5
46.4
56.4
-12.7%
Operating margin
4.5%
4.9%
6.3%
Pre-tax income
31.2
36.4
49.9
-14.4%
Income tax
14.3
1.3
11.1
+1,038.7%
Effective tax rate
45.8%
3.4%
22.2%
Net income
16.9
35.1
38.8
-51.9%
Net margin
1.9%
3.7%
4.3%
Diluted EPS
$0.32
$0.67
$0.74
-52.2%
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2015
FY2014
FY2013
On the year
Last 8 years
Operating cash flow
127
140
85.1
-8.8%
Capital expenditure
122
73.6
62.2
+66.0%
Free cash flow
5.0
65.9
22.9
-92.5%
Free cash flow margin
0.5%
7.0%
2.6%
Cash from investing
-122
-106
-596
Cash from financing
-33.2
-20.7
462
Depreciation and amortisation
86.1
81.7
65.5
+5.3%
Share-based compensation
14.1
13.1
11.0
+7.8%
Buybacks
39.0
0.0
50.0
Diluted shares, weighted
52m
52m
52m
-0.5%
Shares outstanding at period end
52m
52m
51m
-0.7%
Balance sheet
$ million
FY2015
FY2014
FY2013
On the year
Last 8 years
Shareholders' equity
826
838
769
-1.4%
Short-term borrowings
n/a
0.0
5.6
Debt
430
440
480
-2.2%
Other liabilities
229
236
207
-3.0%
Total liabilities and equity
1,485
1,514
1,462
-1.9%
Fixed assets
322
271
257
+18.6%
Goodwill
334
337
330
-0.7%
Intangible assets
245
271
264
-9.8%
Cash and equivalents
161
192
179
-16.5%
Receivables
146
165
170
-11.4%
Inventory
211
198
184
+6.8%
Other assets
67.0
80.1
77.1
-16.3%
Total assets
1,485
1,514
1,462
-1.9%
10-K for the year ended 28 March 2015, filed 22 May 2015: the filing.